Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Traws Pharma (TRAW) Enterprise Value (2016 - 2026)

Traws Pharma (TRAW) has disclosed Enterprise Value for 14 consecutive years, with -$3.8 million as the latest value for Q4 2025.

  • For Q4 2025, Enterprise Value rose 82.1% year-over-year to -$3.8 million; the TTM value through Dec 2025 reached -$3.8 million, up 82.1%, while the annual FY2025 figure was -$3.8 million, 82.1% up from the prior year.
  • Enterprise Value hit -$3.8 million in Q4 2025 for Traws Pharma, up from -$6.4 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$3.8 million in Q4 2025 and bottomed at -$59.4 million in Q3 2021.
  • Average Enterprise Value over 5 years is -$29.7 million, with a median of -$27.5 million recorded in 2023.
  • Year-over-year, Enterprise Value crashed 189.46% in 2021 and then surged 82.1% in 2025.
  • Traws Pharma's Enterprise Value stood at -$55.1 million in 2021, then grew by 29.62% to -$38.8 million in 2022, then skyrocketed by 46.28% to -$20.8 million in 2023, then dropped by 2.48% to -$21.3 million in 2024, then soared by 82.1% to -$3.8 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$3.8 million, -$6.4 million, and -$13.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.